• Vaccine Ontology ID: VO_0004005
• Type: Subunit vaccine
• Status: Research
• Antigen: N-terminal fragment of choline binding protein A (CbpA) (Ogunniyi et al., 2001).
• CbpA gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001250
  • Description: Monophospholipid A (MPL) and aluminium phosphate (AlPO4) (Ogunniyi et al., 2001).
• Adjuvant:
  • VO ID: VO_0000128
  • Description: Monophospholipid A (MPL) and aluminium phosphate (AlPO4) (Ogunniyi et al., 2001).
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: 5- to 6-week-old male BALB/c mice (13 to 15 per group) were immunized intraperitoneally with either adjuvant alone, adjuvant plus CbpA, or CbpA alone. Each mouse received three doses of 10 μg of each protein antigen in either formulation (AlPO4 or MPL plus AlPO4) at 12- to 14-day intervals (Ogunniyi et al., 2001).
• Challenge Protocol: Intraperitoneal-challenge experiments were carried out 2 weeks after the third immunization using a highly virulent capsular type 2 strain (D39). Groups of immunized BALB/c mice were infected with either 1.3 × 10^5 or 1.3 × 10^7 CFU of the challenge strain. The challenge dose was equivalent to approximately 10^3 or 10^5 times the 50% lethal dose (LD50), respectively, for BALB/c mice. The mice were closely monitored for 21 days, and the survival time of each mouse was recorded (Ogunniyi et al., 2001).
• Efficacy: CbpA was able to protect mice from intraperitoneal challenge with medium to very high doses of a highly virulent capsular type 2 pneumococcal strain, D39 (Ogunniyi et al., 2001).